YU33101A - Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži - Google Patents
Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadržiInfo
- Publication number
- YU33101A YU33101A YU33101A YU33101A YU33101A YU 33101 A YU33101 A YU 33101A YU 33101 A YU33101 A YU 33101A YU 33101 A YU33101 A YU 33101A YU 33101 A YU33101 A YU 33101A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- controlled release
- layer
- producing
- release bead
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Perla sa kontrolisanim oslobadjanjem koju čini: (i) jedinično jezgro od inertnog materijala znatno rastvornog u vodi ili koji bubri u vodi; (ii) prvi sloj na jediničnom jezgru od polimera koji je znatno nerastvoran u vodi, (iii) drugi sloj koji pokriva prvi sloj i sadrži aktivnu materiju; i (iv) treći sloj polimera na drugom sloju efikasan u kontroli oslobadjanja aktivne supstance, gde je prvi sloj promenjen da kontroliše prodiranje vode u jezgro. Takodje je otkriven postupak za proizvodnju perli sa kontrolisanim oslobadjanjem.[A controlled release bead comprises: (i) a core unit of a substantially water-soluble or water-swellable inert material; (ii) a first layer on the core unit of a substantially water-insoluble polymer; (iii) a second layer covering the first layer and containing an active ingredient; and (iv) a third layer of polymer on the second layer effective for controlled release of the active ingredient, wherein the first layer is adapted to control water penetration into the core. A method of producing the controlled release bead is also disclosed.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9803871A SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Therapeutic method and formulation |
| PCT/SE1999/001463 WO2000012069A1 (en) | 1998-08-27 | 1999-08-26 | Therapeutic formulation for administering tolterodine with controlled release |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU33101A true YU33101A (sh) | 2003-10-31 |
| RS49891B RS49891B (sr) | 2008-08-07 |
Family
ID=20413266
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US6911217B1 (sh) |
| EP (1) | EP1128819B1 (sh) |
| JP (1) | JP3616011B2 (sh) |
| KR (1) | KR100467384B1 (sh) |
| CN (1) | CN1169522C (sh) |
| AP (1) | AP1323A (sh) |
| AR (1) | AR027815A1 (sh) |
| AT (1) | ATE247458T1 (sh) |
| AU (1) | AU762410B2 (sh) |
| BG (1) | BG65149B1 (sh) |
| BR (1) | BRPI9915142B8 (sh) |
| CA (1) | CA2350061C (sh) |
| CZ (1) | CZ299582B6 (sh) |
| DE (1) | DE69910604T2 (sh) |
| DK (1) | DK1128819T3 (sh) |
| EA (1) | EA005074B1 (sh) |
| EE (1) | EE05232B1 (sh) |
| ES (1) | ES2204193T3 (sh) |
| GE (1) | GEP20022833B (sh) |
| HK (1) | HK1040917B (sh) |
| HR (1) | HRP20010333B1 (sh) |
| HU (1) | HU226582B1 (sh) |
| ID (1) | ID30039A (sh) |
| IL (1) | IL142809A0 (sh) |
| IS (1) | IS2370B (sh) |
| MA (1) | MA25325A1 (sh) |
| MY (1) | MY122195A (sh) |
| NO (1) | NO331399B1 (sh) |
| NZ (1) | NZ511430A (sh) |
| OA (1) | OA11673A (sh) |
| PL (1) | PL195780B1 (sh) |
| PT (1) | PT1128819E (sh) |
| RS (1) | RS49891B (sh) |
| SE (1) | SE9803871D0 (sh) |
| SI (1) | SI1128819T1 (sh) |
| SK (1) | SK284758B6 (sh) |
| TW (2) | TWI222879B (sh) |
| UA (1) | UA57165C2 (sh) |
| WO (1) | WO2000027364A1 (sh) |
| ZA (1) | ZA200103575B (sh) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU728395B2 (en) * | 1996-07-19 | 2001-01-11 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
| EP0957073A1 (en) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| EE05191B1 (et) * | 1999-11-11 | 2009-08-17 | Pharmacia Ab | Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine |
| EP1536780A1 (en) * | 2002-08-28 | 2005-06-08 | Pharmacia Corporation | Oral liquid tolterodine composition |
| US8168170B2 (en) | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
| AU2004206110A1 (en) * | 2003-01-22 | 2004-08-05 | Pfizer Health Ab | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| CA2529984C (en) | 2003-06-26 | 2012-09-25 | Isa Odidi | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors |
| CA2537103C (en) | 2003-11-04 | 2010-01-19 | Shire Laboratories, Inc. | Once daily dosage forms of trospium |
| AU2004289222B2 (en) | 2003-11-04 | 2010-01-21 | Supernus Pharmaceuticals Inc. | Compositions of quaternary ammonium containing bioavailability enhancers |
| US20050152884A1 (en) | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
| US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
| US8894991B2 (en) | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
| US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| EP1629834A1 (en) | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
| EP1836156A1 (en) * | 2005-01-10 | 2007-09-26 | Teva Gyogyszergyar Reszvenytarsasag | Substantially pure tolterodine tartrate and process for preparing thereof |
| EP2261323A1 (en) | 2005-05-31 | 2010-12-15 | The Iams Company | Feline probiotic lactobacilli |
| PL1885383T3 (pl) | 2005-05-31 | 2017-06-30 | Iams Europe B.V. | Kocie probiotyczne bifidobakterie |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| EP2997953B1 (en) | 2006-01-18 | 2018-12-26 | Intec Pharma Ltd. | Delivery device for oral intake of an agent |
| US8426391B2 (en) | 2006-02-03 | 2013-04-23 | Proventiv Therapeutics, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| KR100714058B1 (ko) * | 2006-02-06 | 2007-05-02 | 한국유나이티드제약 주식회사 | 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법 |
| MX2008010877A (es) * | 2006-02-24 | 2008-11-25 | Teva Pharma | Tabletas de liberacion prolongada de succinato de metroprolol y metodos para su preparacion. |
| BRPI0708848A2 (pt) * | 2006-03-21 | 2011-06-21 | Teva Pharma | formulação de liberação controlada de tolterodina |
| EP1839649A1 (en) * | 2006-03-31 | 2007-10-03 | LEK Pharmaceuticals D.D. | Coated formulations for tolterodine |
| US9561188B2 (en) * | 2006-04-03 | 2017-02-07 | Intellipharmaceutics Corporation | Controlled release delivery device comprising an organosol coat |
| EP2015735A1 (en) * | 2006-04-21 | 2009-01-21 | Synthon B.V. | Tolterodine beads |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| EP2026766A1 (en) | 2006-05-17 | 2009-02-25 | Synthon B.V. | Tablet composition with a prolonged release of tamsulosin |
| SI2679228T1 (en) | 2006-06-21 | 2018-06-29 | Opko Ireland Global Holdings, Ltd. | THERAPY WITH THE USE OF VITAMIN D ADDITIONAL FIBER AND HORMON RESISTANCE OF VITAMIN D |
| JP2008007458A (ja) * | 2006-06-29 | 2008-01-17 | Freunt Ind Co Ltd | レイヤリング用核粒子とその製造方法 |
| EA018036B1 (ru) | 2006-11-27 | 2013-05-30 | Х. Лундбекк А/С | Гетероариламидные производные |
| WO2008093303A2 (en) | 2007-02-01 | 2008-08-07 | The Iams Company | Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts |
| DK3342405T3 (da) | 2007-04-25 | 2019-11-11 | Opko Ireland Global Holdings Ltd | Kontrolleret frigivelse af 25-hydroxyvitamin d |
| WO2008134523A1 (en) | 2007-04-25 | 2008-11-06 | Proventiv Therapeutics, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| ES2403107T3 (es) | 2007-04-25 | 2013-05-14 | Cytochroma Inc. | Método de tratamiento de insuficiencia y deficiencia de vitamina D |
| CL2008001970A1 (es) * | 2007-07-03 | 2009-03-27 | Synthon Bv | Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva. |
| US8110226B2 (en) * | 2007-07-20 | 2012-02-07 | Mylan Pharmaceuticals Inc. | Drug formulations having inert sealed cores |
| US8486452B2 (en) * | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
| US8871275B2 (en) | 2007-08-08 | 2014-10-28 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
| CN101801350A (zh) * | 2007-08-13 | 2010-08-11 | 阿巴斯迪特宁医药有限公司 | 抗滥用药物、使用方法和制备方法 |
| US20090192228A1 (en) * | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
| US20090214665A1 (en) * | 2008-02-26 | 2009-08-27 | Lai Felix S | Controlled Release Muscarinic Receptor Antagonist Formulation |
| CA2629099A1 (en) * | 2008-04-01 | 2009-10-01 | Pharmascience Inc. | Novel oral controlled release pharmaceutical formulations |
| KR101852042B1 (ko) | 2008-04-02 | 2018-04-25 | 사이토크로마 인코포레이티드 | 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트 |
| US20090311317A1 (en) * | 2008-05-14 | 2009-12-17 | Capricorn Pharma Inc. | Modified release tolterodine formulations |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US8465770B2 (en) | 2008-12-24 | 2013-06-18 | Synthon Bv | Low dose controlled release tablet |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
| AU2010277207B2 (en) * | 2009-07-31 | 2014-06-26 | Sun Pharmaceutical Industries Limited | Multi-layered, multiple unit pharmaceutical compositions |
| WO2011061616A2 (en) | 2009-11-23 | 2011-05-26 | Micro Labs Limited | Extended release compositions containing tolterodine and process for preparing the same |
| WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
| JO3112B1 (ar) | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
| EP3636280A1 (en) | 2010-03-29 | 2020-04-15 | Opko Ireland Global Holdings, Ltd. | Methods and compositions for reducing parathyroid levels |
| CA2793485A1 (en) | 2010-03-29 | 2011-10-06 | Ferring B.V. | A fast dissolving pharmaceutical composition |
| US8748433B2 (en) | 2010-04-30 | 2014-06-10 | Merck Sharp & Dohme Corp. | β3 adrenergic receptor agonists |
| US20120040008A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| WO2012154770A1 (en) | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder |
| GR1007628B (el) | 2011-07-27 | 2012-06-29 | Φαρματεν Αβεε, | Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| WO2013037708A1 (en) | 2011-09-16 | 2013-03-21 | Ferring B.V. | A fast dissolving pharmaceutical composition |
| US20140242158A1 (en) * | 2011-09-30 | 2014-08-28 | Astellas Pharma, Inc. | Granular Pharmaceutical Composition |
| MX2015000541A (es) | 2012-07-12 | 2015-05-11 | Ferring Bv | Formulaciones de diclofenaco. |
| JP2015529255A (ja) * | 2012-09-20 | 2015-10-05 | オーエイチアール ファーマ， エルエルシーＯｈｒ Ｐｈａｒｍａ， Ｌｌｃ | 治療薬の持続放出のための多層の生体分解可能なマイクロ粒子 |
| TW201422254A (zh) * | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
| US20150306170A1 (en) * | 2012-11-21 | 2015-10-29 | Ferring B.V. | Composition for immediate and extended release |
| EP2968579B1 (en) * | 2013-03-13 | 2020-04-15 | Intervet International B.V. | Stable bioactive substances and methods of making |
| CA2907428A1 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| AU2014246617A1 (en) | 2013-12-23 | 2015-07-09 | Sun Pharmaceutical Industries Limited | Multi-layered, multiple unit pharmaceutical compositions |
| SG10201911274TA (en) | 2014-08-07 | 2020-02-27 | Opko Ireland Global Holdings Ltd | Adjunctive therapy with 25-hydroxyvitamin d |
| US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
| CA2936748C (en) * | 2014-10-31 | 2017-08-08 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| WO2017146053A1 (ja) * | 2016-02-23 | 2017-08-31 | ニプロ株式会社 | 医薬組成物粒子とそれを含む口腔内崩壊製剤 |
| SG10201913863TA (en) | 2016-03-28 | 2020-03-30 | Opko Ireland Global Holdings Limited | Methods of vitamin d treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1144911B (it) * | 1981-03-19 | 1986-10-29 | Pharmatec Spa | Composizione farmaceutica a rilascio controllato contenente ibuprofen |
| JPH07107450A (ja) | 1993-10-08 | 1995-04-21 | Hitachi Ltd | 情報通信装置 |
| JP3453186B2 (ja) | 1994-04-14 | 2003-10-06 | 共和薬品工業株式会社 | 徐放性マイクロカプセルおよびその製造方法 |
| SE9402422D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New beads for controlled release and a pharmaceutical preparation containing the same |
| US5645858A (en) * | 1994-10-06 | 1997-07-08 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
| US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| AU728395B2 (en) | 1996-07-19 | 2001-01-11 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| US6312728B1 (en) * | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
-
1998
- 1998-11-11 SE SE9803871A patent/SE9803871D0/xx unknown
-
1999
- 1999-11-11 SK SK625-2001A patent/SK284758B6/sk not_active IP Right Cessation
- 1999-11-11 CA CA002350061A patent/CA2350061C/en not_active Expired - Lifetime
- 1999-11-11 AP APAP/P/2001/002166A patent/AP1323A/en active
- 1999-11-11 CZ CZ20011627A patent/CZ299582B6/cs not_active IP Right Cessation
- 1999-11-11 EE EEP200100254A patent/EE05232B1/xx unknown
- 1999-11-11 PT PT99971702T patent/PT1128819E/pt unknown
- 1999-11-11 AT AT99971702T patent/ATE247458T1/de active
- 1999-11-11 JP JP2000580595A patent/JP3616011B2/ja not_active Expired - Lifetime
- 1999-11-11 CN CNB998132160A patent/CN1169522C/zh not_active Expired - Lifetime
- 1999-11-11 PL PL99348612A patent/PL195780B1/pl unknown
- 1999-11-11 NZ NZ511430A patent/NZ511430A/en not_active IP Right Cessation
- 1999-11-11 OA OA1200100112A patent/OA11673A/en unknown
- 1999-11-11 EA EA200100538A patent/EA005074B1/ru not_active IP Right Cessation
- 1999-11-11 DK DK99971702T patent/DK1128819T3/da active
- 1999-11-11 AU AU14366/00A patent/AU762410B2/en not_active Expired
- 1999-11-11 ES ES99971702T patent/ES2204193T3/es not_active Expired - Lifetime
- 1999-11-11 HU HU0105038A patent/HU226582B1/hu unknown
- 1999-11-11 UA UA2001042824A patent/UA57165C2/uk unknown
- 1999-11-11 MY MYPI99004911A patent/MY122195A/en unknown
- 1999-11-11 KR KR10-2001-7005879A patent/KR100467384B1/ko active IP Right Grant
- 1999-11-11 EP EP99971702A patent/EP1128819B1/en not_active Expired - Lifetime
- 1999-11-11 US US09/763,281 patent/US6911217B1/en not_active Expired - Lifetime
- 1999-11-11 AR ARP990105734A patent/AR027815A1/es active IP Right Grant
- 1999-11-11 SI SI9930411T patent/SI1128819T1/xx unknown
- 1999-11-11 ID IDW00200101038A patent/ID30039A/id unknown
- 1999-11-11 IL IL14280999A patent/IL142809A0/xx unknown
- 1999-11-11 RS YUP-331/01A patent/RS49891B/sr unknown
- 1999-11-11 WO PCT/SE1999/002052 patent/WO2000027364A1/en active IP Right Grant
- 1999-11-11 DE DE69910604T patent/DE69910604T2/de not_active Expired - Lifetime
- 1999-11-11 GE GEAP19995939A patent/GEP20022833B/en unknown
- 1999-11-11 BR BRPI9915142A patent/BRPI9915142B8/pt not_active IP Right Cessation
-
2000
- 2000-02-11 TW TW089102338A patent/TWI222879B/zh not_active IP Right Cessation
- 2000-02-11 TW TW089102332A patent/TWI267385B/zh not_active IP Right Cessation
-
2001
- 2001-05-03 ZA ZA200103575A patent/ZA200103575B/en unknown
- 2001-05-09 IS IS5936A patent/IS2370B/is unknown
- 2001-05-10 NO NO20012314A patent/NO331399B1/no not_active IP Right Cessation
- 2001-05-10 HR HR20010333A patent/HRP20010333B1/xx not_active IP Right Cessation
- 2001-06-08 MA MA26228A patent/MA25325A1/fr unknown
- 2001-06-08 BG BG105582A patent/BG65149B1/bg unknown
-
2002
- 2002-04-04 HK HK02102521.2A patent/HK1040917B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU33101A (sh) | Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži | |
| MXPA02004574A (es) | Formulacion farmaceutica que contiene tolterodina y su uso. | |
| AU2684497A (en) | Biodegradable sustained-release preparation, biodegradable pheromone dispenser and biodegradable pest controlling agent | |
| PL397728A1 (pl) | Zastosowanie kompozycji herbicydów, sposób zwalczania szkodliwych roślin i preparat chwastobójczy | |
| AU6853698A (en) | Method and device for exposure control, method and device for exposure, and method of manufacture of device | |
| DE59507193D1 (de) | VERFAHREN ZU hERSTELLUNG EINER MANTELTABLETTE MIT SPITZEM KERN | |
| AU8109398A (en) | Implants for controlled release of pharmaceutically active principles and method for making same | |
| AU2499100A (en) | Method and apparatus for selectively controlling the quantum state probability distribution of entangled quantum objects | |
| AU2963400A (en) | Improved controlled release compositions and method | |
| AU698240B2 (en) | Composition providing selective release of an active ingredient | |
| AU7599100A (en) | Control method and system for use when growing thin-films on semiconductor-basedmaterials | |
| EP0741109A3 (en) | Method and composition for enhancing biocidal activity | |
| AU7569796A (en) | Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds. | |
| AU2001293077A1 (en) | System and method for distributed multi-party call control | |
| MX9603645A (es) | Materiales antimicrobianos. | |
| AU3090999A (en) | Artificial surface active lure apparatus and method | |
| AU3708100A (en) | Method for protecting and/or controlled release of active ingredients | |
| WO2002005200A8 (en) | A method, an apparatus, and a composition for customizing the combination of fragrances | |
| AU1534895A (en) | Weed-suppressing agent, method for preparing it and its use in weed control | |
| AU3828697A (en) | Granulated formulation and method for stabilizing biocontrol agents | |
| MY122558A (en) | Solid crop protection formulation | |
| CA2414753A1 (en) | Dermal therapeutic system containing 2-(3-benzophenyl)-propionic acid or [0-(2,6-dichloranilino)-phenyl]-ethanoic acid | |
| AU9693598A (en) | Formulations and methods for insect control | |
| AU1092095A (en) | Intra-uterine ring for the release of an active agent, such as a hormone, and an introducer | |
| CA2349114A1 (en) | Insecticidal mat and heat-transpiration insecticidal method using the same |